Navigation Links
Cepheid Reports 2013 First Quarter Results
Date:4/18/2013

er unforeseen supply, development and manufacturing problems; the potential need for additional intellectual property licenses for tests and other products and the terms of such licenses; lengthy sales cycles in certain markets; the Company's reliance on distributors in some regions to market, sell and support its products; the occurrence of unforeseen expenditures, acquisitions or other transactions; costs associated with litigation; the impact of competitive products and pricing; the Company's ability to manage geographically-dispersed operations; and underlying market conditions worldwide.  Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K and its other reports filed with the Securities and Exchange Commission.

All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.

FINANCIAL TABLES FOLLOWCEPHEIDCONDENSED CONSOLIDATED UNAUDITED STATEMENTS OF OPERATIONS(in thousands, except per share data)Three Months Ended March 31, 20132012Sales:System and other sales

$
,010$
5,230Reagent and disposable sales

75,92862,062Total sales

91,93877,292Costs and operating expenses:Cost of sales 

42,89235,608Collaboration profit sharing 

2,1101,684Research and development

17,72722,102Sales and marketing

19,12614,512General and administrative

9,76311,051Total costs and operating expenses 

91,61884,957Income (loss) from operations 

320(7,665)Other income, net

374238Income (loss) before income taxes

694(7,427)Benefit from (provision for) income taxes

(381)1,901Net income (loss)

$
313$
(5,526)Basic net income (
'/>"/>

SOURCE Cepheid
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
2. Cepheid Announces Board of Directors Changes
3. Cepheid Reports 2012 Second Quarter Results
4. Cepheid Receives FDA Clearance for GeneXpert Infinity-80 System for Initial Use with Xpert Flu Assay
5. Cepheid Announces European Release of Xpert CT/NG and Xpert CT, Delivering Rapid Detection and Differentiation of Chlamydia and Gonorrhoeae
6. Diagnostic Marketing Association Names Cepheid 2011 Marketer of the Year
7. Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria
8. Cepheid to Webcast Upcoming Financial Presentations
9. Cepheid Reports Fourth Quarter and Full Year 2011 Results
10. Cepheid Welcomes Senior Vice President of Human Resources
11. Global Nano-Materials Market 2002-2016: Nano-Materials Industry, Production Volumes, Revenues and End User Market Demand - MarketResearchReports.Biz
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... (PRWEB) April 17, 2015 Global ... the GTCbio Stem Cell Summit 2015 April 27 - ... the latest developments in all areas of stem cell ... of stem cells and regenerative medicine. , The ... trials, as well as translational research in stem cell ...
(Date:4/16/2015)... and OSAKA, Japan , ... Research Application (CiRA) of Kyoto University and Takeda ... will work together to develop clinical applications of ... heart failure, diabetes mellitus, neurological disorders and cancer ... Applications" (T-CiRA) is designed to expedite multiple research ...
(Date:4/16/2015)... CA (PRWEB) April 16, 2015 ... the Buzz of BIO Contest for the ... Organization (BIO), the 2015 BIO International Convention will take ... Philadelphia, Pennsylvania. During the Buzz of BIO contest, industry ... to see present at the conference. The community voting ...
(Date:4/16/2015)... CHARLOTTE, N.C. (PRWEB) April 16, 2015 ... North Carolina at Charlotte (UNC Charlotte) spin-out company, ... David L. Cooper, Ph.D., M.D., as Chief Operating ... 20 years of experience in developing clinical diagnostic ... oncology and infectious disease. , Cooper’s extensive career ...
Breaking Biology Technology:Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 3CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 3OncoTAb Names Dr. David L. Cooper as COO 2
... May 13 /Xinhua-PRNewswire/ -- Chindex International,Inc. (Nasdaq: CHDX ... and products in the People,s Republic of China,announced that ... and Exchange Commission (SEC) that, if declared effective by ... to time, up to $100 million,of its common stock ...
... /Xinhua-PRNewswire/ -- Chindex International,Inc. (Nasdaq: CHDX ) a ... in the People,s Republic of China,announced that it intends ... March 31, 2008, on Thursday, June 12, 2008., ... Thursday, June,12, 2008 at 9:00 a.m. Eastern Time to ...
... Patients Shipped in the Quarter ... ... BEDFORD, Mass., May 13 Insulet Corporation,(Nasdaq: PODD ), a ... today announced financial results for,the first quarter ended March 31, 2008., ...
Cached Biology Technology:Chindex International Announces Shelf Registration, Related Strategy and Guidance 2Chindex International Announces Shelf Registration, Related Strategy and Guidance 3Chindex International Announces Shelf Registration, Related Strategy and Guidance 4Chindex International Announces Shelf Registration, Related Strategy and Guidance 5Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Fourth Quarter and Year End Results on Thursday, June 12, 2008 2Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Fourth Quarter and Year End Results on Thursday, June 12, 2008 3Insulet Reports First Quarter 2008 Results 2Insulet Reports First Quarter 2008 Results 3Insulet Reports First Quarter 2008 Results 4Insulet Reports First Quarter 2008 Results 5Insulet Reports First Quarter 2008 Results 6Insulet Reports First Quarter 2008 Results 7
(Date:4/10/2015)... April 10, 2015 Research and ... the "Security Competitive Profiles - NEC" report ... NEC will continue to supply a range ... market, with a company focus on the development of ... Winning opportunities in the Asia-Pacific ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
(Date:4/2/2015)... , April 2, 2015 ... DERMALOG by far outperforms the strongest competitors, showing ... high accuracy, the system is capable of a ... speed proves up to be ten times faster ... its runner-up performance.      (Photo: ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... has already had dramatic effects on individual species, with ... migration. But, in a new study from the open-access ... Getz show that the impact of climate change on ... by a top predator - the reintroduced gray wolf ...
... A newly discovered mechanism by which an infectious fungus ... virulence, according to Howard Hughes Medical Institute investigators at ... in light following fungal invasion of the human body ... sparks infection, the researchers said. , The discovery in ...
... damage to the heart that can cause congestive ... limited ability of the myocardium to regenerate and ... now document the existence of a previously unrecognized ... therapeutic potency for myocardial tissue regeneration following myocardial ...
Cached Biology News:Gray wolves maintain the food chain in winter 2Light therapy may combat fungal infections, new evidence suggests 2Light therapy may combat fungal infections, new evidence suggests 3
Request Info...
Goat polyclonal to MLH3 Immunogen: Synthetic peptide: RQSLQQSMPPCEPP (Human) from C Terminus of the protein sequence according to NP_055196....
IRF7 Immunogen: Synthetic peptide corresponding to residues E(463) G T Q R E G V S S L D S S S(477) of human IRF7. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Rabbit polyclonal to NMDAR1 e/f/g/h ( Abpromise for all tested applications)....
Biology Products: